MedTrace Logo

Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia

NCT04713878 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-01-20

No results posted yet for this study

Summary

Due to the cytokine storm that develops as a result of Coronavirus Disease 2019 (COVID-19) infection, some patients hospitalization to intensive care cause of pneumonia, Acute Respiratory Distress Syndrome (ARDS) and multiple organ failure. Mortality is higher in treatment-resistant cases.

Purpose of this study:

1. Providing immune modulation by Stem Cell Transplantation and reducing the damage caused by cytokine storm to tissues and organs,
2. Correcting immunosuppression and fight against COVID-19 virus by editing B and T cells,
3. It is to accelerate healing in organ damage by increasing growth factors through mesenchymal stem cells.

Primary outcome: Improvement of clinical symptoms, reduction of cytokine storm Secondary outcome: Recovery of patients; from mechanical ventilation

Conditions

  • Coronavirus Disease 2019 (COVID-19) Pneumonia

Interventions

OTHER

Mesenchymal stem cells

Intravenous infusion of Mesenchymal stem cells

Sponsors & Collaborators

  • Kanuni Sultan Suleyman Training and Research Hospital

    lead OTHER

Principal Investigators

  • Ebru Kaya, MD · Kanuni Sultan Suleyman Education and Training Hospital

  • Gursel Turgut, Prof Dr · Genkord

  • Ali Kocatas, MD · Kanuni Sultan Suleyman Education and Training Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-08
Primary Completion
2020-06-30
Completion
2020-07-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04713878 on ClinicalTrials.gov